Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

Author(s):
Kriege, M.; Jager, A.; Hollestelle, A.; Berns, E.M.J.J.; Blom, J.; Meijer-van Gelder, M.; Sieuwerts, A.M.; Ouweland, A. van den; Collee, J.M.; Kroep, J.R.; Martens, J.W.M.; Hooning, M.J.; Seynaeve, C.
Published
2015
Publication type
Article / Letter to editor
Metastatic breast cancerCHEK2 1100delCChemotherapyEndocrine therapyResponseSurvival
Date issued
2015-10-31
Language
English
Is part of
Journal of Cancer Research and Clinical Oncology (2015), Vol. 141, no. 10, p. 1879-1887
hdl
1887/108005
doi
10.1007/s00432-015-1981-7